ClinConnect ClinConnect Logo
Search / Trial NCT06506721

Comparison Between Two Medical Devices for Labor Induction After Previous C-section

Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Jul 16, 2024

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Trial Of Labour

ClinConnect Summary

This clinical trial is looking at two different medical devices, the Dilapan-S and the Cook Balloon, to help induce labor in women who have had a previous cesarean section (C-section). Inducing labor means starting labor artificially when it doesn’t start on its own, which can be necessary for various medical reasons. The study aims to find out which device is more effective by measuring how long it takes from when the device is placed until the baby is delivered. Additionally, the researchers will look at how often women need another C-section and how satisfied they are with the induction process.

To participate in this study, women must be at least 18 years old, have had one previous C-section, and be between 24 to 42 weeks pregnant with a low Bishop Score (a score that helps assess how ready the body is for labor). Some women may not be eligible if they have certain conditions like multiple C-sections, infections, or specific pregnancy complications. If you join the trial, you’ll receive one of the two devices to help with labor induction, and your progress and experiences will be closely monitored throughout the process. This study is important because it aims to provide better information on how to safely induce labor in women with a history of C-sections.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • All women \>= 18years old with a previous CS and an indication of labour induction, between 24-42 weeks of pregnancy.
  • Modified Bishop-Score \< 6
  • Informed consent
  • Exclusion criteria:
  • More than 1 CS
  • Premature rupture of membranes
  • Vaginal infection
  • Intrauterine fetal demise
  • Twin pregnancy
  • Contraindication against labour induction or vaginal delivery
  • Vaginal bleeding
  • Simultaneous external administration of prostaglandins planned
  • Placenta praevia, vasa praevia or placenta accreta spectrum
  • Transverse fetal orientation
  • Prolapsed umbilical cord
  • Prior hysterotomy, classic uterine incision, myomectomy or any other full thickness uterine incision (except C-section)
  • Pelvic structural anomaly
  • Active genital herpes infection
  • Invasive cervical cancer
  • Abnormal fetal heart rate pattern
  • Breech presentation
  • Maternal heart disease
  • Polyhydramnios
  • Presentic part above the pelvic inlet
  • Severe maternal hypertension

About Insel Gruppe Ag, University Hospital Bern

Insel Gruppe AG, the umbrella organization for the University Hospital Bern, is a leading healthcare provider in Switzerland, renowned for its commitment to advancing medical research and patient care. As a key player in clinical trials, Insel Gruppe AG integrates cutting-edge scientific inquiry with clinical excellence, facilitating innovative studies that span a wide range of medical disciplines. The institution prioritizes collaboration with academic partners and industry stakeholders to enhance the understanding of diseases and develop effective treatment options, ultimately aiming to improve patient outcomes and contribute to the global medical community.

Locations

Bern, , Switzerland

Patients applied

0 patients applied

Trial Officials

Daniel Surbek, Prof. Dr.

Principal Investigator

Co-Chairman, Departament of Obstetrics an Gynäkology, Head of Obstetrics and feto-maternal Medicine, University Hospital Bern

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported